- Home
- AUPH vs AGIO Comparison
AUPH vs AGIO Comparison
Compare AUPH & AGIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AUPH
- AGIO
- Stock Information
- Founded
- AUPH 1993
- AGIO 2007
- Country
- AUPH Canada
- AGIO United States
- Employees
- AUPH 300
- AGIO N/A
- Industry
- AUPH Biotechnology: Pharmaceutical Preparations
- AGIO Biotechnology: Pharmaceutical Preparations
- Sector
- AUPH Health Care
- AGIO Health Care
- Exchange
- AUPH Nasdaq
- AGIO Nasdaq
- Market Cap
- AUPH 1.2B
- AGIO 1.4B
- IPO Year
- AUPH 1999
- AGIO 2013
- Fundamental
- Price
- AUPH $8.93
- AGIO $40.00
- Analyst Decision
- AUPH Strong Buy
- AGIO Buy
- Analyst Count
- AUPH 2
- AGIO 6
- Target Price
- AUPH $11.50
- AGIO $54.60
- AVG Volume (30 Days)
- AUPH 2.1M
- AGIO 672.8K
- Earning Date
- AUPH 07-31-2025
- AGIO 07-31-2025
- Dividend Yield
- AUPH N/A
- AGIO N/A
- EPS Growth
- AUPH N/A
- AGIO N/A
- EPS
- AUPH 0.27
- AGIO 11.45
- Revenue
- AUPH $247,295,000.00
- AGIO $37,035,000.00
- Revenue This Year
- AUPH $12.15
- AGIO $22.30
- Revenue Next Year
- AUPH $18.34
- AGIO $219.19
- P/E Ratio
- AUPH $33.57
- AGIO $3.49
- Revenue Growth
- AUPH 29.20
- AGIO 25.96
- 52 Week Low
- AUPH $5.20
- AGIO $23.42
- 52 Week High
- AUPH $10.67
- AGIO $62.58
- Technical
- Relative Strength Index (RSI)
- AUPH 57.25
- AGIO 65.57
- Support Level
- AUPH $8.73
- AGIO $38.48
- Resistance Level
- AUPH $9.37
- AGIO $41.74
- Average True Range (ATR)
- AUPH 0.41
- AGIO 1.51
- MACD
- AUPH 0.04
- AGIO -0.03
- Stochastic Oscillator
- AUPH 77.28
- AGIO 73.87
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.
About AGIO Agios Pharmaceuticals Inc.
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.